Cytomegalovirus infection commonly occurs in adults during their fourth decade of life. The retina can be affected when the virus spreads via the bloodstream [1]. People infected with the human immunodeficiency virus (HIV) are at a higher risk of acquiring cytomegalovirus retinitis, as the former organism compromises the endothelial integrity of vasculature, and blood flow, in the retina [2]. Retinitis may involve inflammation as well as bleeding of the retina, often in the ocular fundus. Lesions such as cotton wool spots can be visualized on the retina.

HIV further predisposes individuals to cytomegalovirus retinitis due to its immunosuppressive effects. This results in activation of latent infection after the host immunity decreases [3]. Various conditions, such as diabetes mellitus, malignancy, and organ transplantation, impart the same effect [4] [5]. Although cytomegalovirus retinitis in immunocompetent individuals is rare, cases have been reported. It has also been described in patients with systemic lupus erythematosus and other autoimmune diseases, with concomitant use of immunosuppressive drugs [6].

Cytomegalovirus retinitis can be asymptomatic. In symptomatic infection, patients may experience various visual disturbances, including floaters, photopsia, narrowed visual fields, blurred vision, and scotoma [7]. They do not usually complain of red or painful eyes. Blindness can ensue within months of symptom onset. Furthermore, cytomegalovirus retinitis is often initially unilateral before becoming bilateral.

Notably, immunocompromised children do not seem to have increased susceptibility to this disease [8]. Cytomegalovirus retinitis can also be congenital, occurring in 25% of babies already exhibiting other features of CMV infection, and does not usually worsen after birth.

The ophthalmologic examination is the diagnostic procedure employed. This involves dilating the pupils to visualize internal ocular structures through ophthalmoscopy.

CMV infection can be detected through biochemical analysis of blood and urine samples. Furthermore, a biopsy would reveal viral organisms in the tissue, however, this is not a routine procedure.

It is good practice to screen all patients at risk of cytomegalovirus retinitis, including those that lack symptoms, because early stage diagnosis and treatment are uncomplicated, and in addition, a significant proportion of individuals are asymptomatic at the time of diagnosis. Furthermore, intervention prevents blindness, which is a highly debilitating sequela of cytomegalovirus retinitis. Screening via testing visual acuity of patients using a Snellen chart is insufficient, as only a small portion of the retina, the fovea, is assessed in this way. The use of questionnaires specifically tailored to detect or elicit signs and symptoms of cytomegalovirus retinitis can be a more effective screening tool.

HIV patients have a higher risk of cytomegalovirus retinitis, and it is reported that the latter is the most frequently encountered opportunistic viral infection in the above group, especially when CD4 (cluster of differentiation 4) cell count is extremely low, that is, less than 50 per cubic millimeter [9]. Immunocompetent individuals, especially those who have received steroid injections, make up the minority of cytomegalovirus retinitis patients [10] [11].

Treatment for CMV Retinitis focuses on controlling the infection and preserving vision. Antiviral medications, such as ganciclovir, foscarnet, or cidofovir, are commonly used. These can be administered orally, intravenously, or directly into the eye. Regular monitoring and follow-up are crucial to assess the response to treatment and adjust the therapy as needed. In some cases, surgery may be required to repair retinal detachment.

The prognosis for CMV Retinitis varies depending on the timeliness of diagnosis and treatment. Early intervention can help control the infection and prevent severe vision loss. However, if left untreated, the condition can lead to permanent blindness. Patients with compromised immune systems may experience recurrent episodes, necessitating ongoing management and monitoring.

CMV Retinitis is caused by the cytomegalovirus, which is part of the herpesvirus family. The virus is widespread and can remain dormant in the body for long periods. It typically becomes active and causes retinitis in individuals with weakened immune systems, such as those with HIV/AIDS, undergoing chemotherapy, or taking immunosuppressive drugs after organ transplantation.

CMV Retinitis is relatively rare in the general population but is more prevalent among individuals with compromised immune systems. Before the advent of effective antiretroviral therapy, it was a common complication in patients with advanced HIV/AIDS. With improved treatments, the incidence has decreased significantly, but it remains a concern for those with severe immunosuppression.

The pathophysiology of CMV Retinitis involves the reactivation of the cytomegalovirus in the retina. The virus causes inflammation and damage to the retinal cells, leading to necrosis (cell death) and retinal detachment. The immune system's inability to control the virus allows it to spread and cause extensive damage, resulting in vision loss.

Preventing CMV Retinitis involves managing the underlying conditions that weaken the immune system. For individuals with HIV/AIDS, maintaining a strong immune system through antiretroviral therapy is crucial. Organ transplant recipients and others on immunosuppressive therapy should be monitored closely for signs of CMV infection. Prophylactic antiviral medications may be considered in high-risk patients to prevent the onset of retinitis.

Cytomegalovirus Retinitis is a serious eye infection that can lead to vision loss, primarily affecting individuals with weakened immune systems. Early diagnosis and treatment with antiviral medications are essential to control the infection and preserve vision. Ongoing monitoring and management are necessary to prevent recurrence and manage complications.

If you have a weakened immune system and experience symptoms like blurred vision or floaters, it's important to seek medical attention promptly. CMV Retinitis can be effectively managed with early intervention, helping to preserve your vision and quality of life. Regular eye exams and adherence to prescribed treatments are key components of managing this condition.

1. López-Contreras J, Ris J, Domingo P, Puig M, Rabella N, Nolla J. Disseminated cytomegalovirus infection in an immunocompetent adult successfully treated with ganciclovir. Scand J Infect Dis. 1995;27(5):523-525.
2. Glasgow BJ, Weisberger AK. A quantitative and cartographic study of retinal microvasculopathy in acquired immunodeficiency syndrome. Am J Ophthalmol. 1994;118(1):46-56.
3. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol. 2008;325:417-470.
4. Bhat V, Joshi A, Sarode R, Chavan P. Cytomegalovirus infection in the bone marrow transplant patient. World J Transplant. 2015;5(4):287–291.
5. Vertes D, Snyers B, De Potter P. Cytomegalovirus retinitis after low-dose intravitreous triamcinolone acetonide in an immunocompetent patient: a warning for the widespread use of intravitreous corticosteroids. Int Ophthalmol. 2010;30(5):595-597.
6. Kelkar A, Kelkar J, Kelkar S, Bhirud S, Biswas J. Cytomegalovirus retinitis in a seronegative patient with systemic lupus erythematosus on immunosuppressive therapy. J Ophthalmic Inflamm Infect. 2011;1(3):129–132.
7. Wei LL, Park SS, Skiest DJ. Prevalence of visual symptoms among patients with newly diagnosed cytomegalovirus retinitis. Retina. 2002;22(3):278-282.
8. Baumal CR, Levin AV, Kavalec CC, Petric M, Khan H, Read SE. Screening for CMV retinitis in children. Arch Pediatr Adolesc Med. 1996;150(11):1186-1192.
9. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-683.
10. Gupta S, Vemulakonda GA, Suhler EB, et al. Cytomegalovirus retinitis in the absence of AIDS. Can J Ophthalmol. 2013;48(2):126-129.
11. Saidel MA, Berreen J, Margolis TP. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol. Am J Ophthalmol. 2005;140(6):1141-1143.